Leading Innovative Vaccine/Bio Technology SK bioscienceFrom Prevention To Cure
Our Science & Technology
News SK bioscience’s COVID-19 Vacci...
Phase I/II stage 1 confirms 5~8 folds of neutraliz...More
News SK Bioscience Submitted Phase ...
GBP510 submitted for Phase 3 clinical study in Kor...More
News SK bioscience reinforces respo...
ESG Committee will review major management strate...More
News SK bioscience to Sign MOU with...
SK invested about 150 billion won in the expansio...More
- SKY Cellflu prefilled syringe
- SKY Cellflu Quadrivalent prefilled syringe
- SKY Zoster Inj.
- SKY Varicella Inj.
The first flu vaccine developed by using the cell-culturing method in Korea. It can provide a large amount of vaccine in a short period of time, as this method can produce a large amount of specific cells which are necessary for cultivating viruses in advance. Furthermore, people with egg allergies can be inoculated at the same time.
The world’s first WHO PQ-certified Quadrivalent flu vaccine developed by next-generation technology. Cell culture-derived method reduces the possibility of mutations that can occur in the incubation process, and has a high preventive effect.
Prefilled syringe-typed shingles vaccine that increases convenience and stability. It is manufactured in a way that is gaining global attention due to its high convenience, accurate dosage, and prevention of contamination when preparing for injection.
The world’s second WHO PQ-certified chickenpox virus vaccine, it was developed in Korea through a process of cell culture, virus infection, and refinement using the latest sterile production system.